Literature DB >> 9861414

Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi.

A D Harries1, D S Nyangulu, C Kang'ombe, D Ndalama, J R Glynn, H Banda, J J Wirima, F M Salaniponi, G Liomba, D Maher, P Nunn.   

Abstract

There is little information about treatment outcome in patients with smear-negative pulmonary tuberculosis (PTB) or extrapulmonary tuberculosis (EPTB) treated under routine programme conditions in subsaharan Africa. A prospective study was carried out to determine treatment outcome in an unselected cohort of TB patients admitted to Zomba General Hospital, Malawi. Eight hundred and twenty-seven adult TB patients (451 men and 376 women) were registered between 1 July and 31 December 1995. Standardized treatment outcomes of treatment completion, death, default, and transfer to another district were assessed in relation to type of TB, human immunodeficiency virus (HIV) serostatus, age and gender. Two hundred and fifty-four patients (31%) died by the end of treatment, half of the deaths occurring in the first month. Death rates were 19% among 386 patients with smear-positive PTB, 46% among 211 patients with smear-negative PTB, and 37% among 230 patients with EPTB; 77% of the patients were HIV seropositive. Among new patients, HIV-positive patients had higher death rates than HIV-negative patients (hazard ratio [HR] 2.5; 95% confidence interval [95% CI] 1.6-3.8). Smear-negative patients had the highest death rates (HR 3.9; 95% CI 2.7-5.5 compared to smear-positive patients), followed by EPTB patients (HR 2.6, 95% CI 1.8-3.7 compared to smear-positive patients). Death rates increased with age but were similar in men and women. Adult patients in Malawi with smear-negative PTB and EPTB have low treatment completion and high death rates, related to high levels of HIV infection. National TB control programmes in areas of high HIV prevalence should no longer ignore treatment outcomes in patients with smear-negative PTB or EPTB.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9861414     DOI: 10.1016/s0035-9203(98)91036-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  23 in total

1.  HIV Treatment in Developing Countries.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

Review 2.  Impact of HIV infection on tuberculosis.

Authors:  A Zumla; P Malon; J Henderson; J M Grange
Journal:  Postgrad Med J       Date:  2000-05       Impact factor: 2.401

3.  Timing of antiretroviral therapy and effects on tuberculosis treatment outcomes in HIV-co-infected patients in Malawi.

Authors:  H S Kanyerere; J Mpunga; H Tweya; M Edginton; A D Harries; S G Hinderaker; F Chimbwandira; A Gonani; K Mbendera
Journal:  Public Health Action       Date:  2012-10-30

Review 4.  HIV-associated tuberculosis and cryptococcosis in resource-limited settings.

Authors:  Umesh G Lalloo; Farida C Amod
Journal:  Curr HIV/AIDS Rep       Date:  2005-08       Impact factor: 5.071

5.  Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana.

Authors:  Taraz Samandari; David Bishai; Michiel Luteijn; Barudi Mosimaneotsile; Oaitse Motsamai; Maarten Postma; Gijs Hubben
Journal:  Am J Respir Crit Care Med       Date:  2010-12-10       Impact factor: 21.405

6.  Prevalence and indicators of HIV and AIDS among adults admitted to medical and surgical wards in Blantyre, Malawi.

Authors:  David K Lewis; Maria Callaghan; Kamija Phiri; James Chipwete; James G Kublin; Eric Borgstein; Ed E Zijlstra
Journal:  Malawi Med J       Date:  2002-09       Impact factor: 0.875

7.  Genetic determinants of drug-resistant tuberculosis among HIV-infected patients in Nigeria.

Authors:  Lana Dinic; Patrick Akande; Emmanuel Oni Idigbe; Agatha Ani; Dan Onwujekwe; Oche Agbaji; Maxwell Akanbi; Rita Nwosu; Bukola Adeniyi; Maureen Wahab; Chindak Lekuk; Chioma Kunle-Ope; Nkiru Nwokoye; Phyllis Kanki
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

8.  Clinical indicators of mycobacteraemia in adults admitted to hospital in Blantyre.

Authors:  D K Lewis; Rph Peters; M J Schijffelen; Grf Joaki; A L Walsh; J G Kublin; J Kumwenda; S Kampondeni; M E Molyneux; E E Zijlstra
Journal:  Malawi Med J       Date:  2003-06       Impact factor: 0.875

9.  Evaluation of the 2007 WHO guideline to improve the diagnosis of tuberculosis in ambulatory HIV-positive adults.

Authors:  Olivier Koole; Sopheak Thai; Kim Eam Khun; Reaksmey Pe; Johan van Griensven; Ludwig Apers; Jef Van den Ende; Tan Eang Mao; Lutgarde Lynen
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

10.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.

Authors:  Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins
Journal:  Lancet       Date:  2011-04-18       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.